However, since these therapeutics induce major side-effects, including elevated risk of cardiovascular diseases, the reinforcement of endogenous EPO production has been suggested as an alternative approach for the treatment of CKD-associated anemia26–28. The gene discussed is EPO; the disease is cardiovascular disorder.